Specific immune cell makes prostate cancer therapy more effective for Black men, study says upi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upi.com Daily Mail and Mail on Sunday newspapers.
Top UK Stocks to Watch: Rio Tinto shares hit record high on bumper payout
Joshua Warner February 17, 2021 9:36 AM
Rio Tinto pays its biggest dividend in its history, BAT expects profits to rise again this year, Imperial Brands gets a new CFO, Greencoat UK Wind and TP ICAP raise equity, and Signature Aviation sells its engine repair business. Share:
Top News: Rio Tinto pays biggest dividend in its history
Rio Tinto said it will pay a record dividend for 2020 after higher commodity prices allowed it book significantly higher margins and profit, sending shares to an all-time high.
The miner said revenue in the year edged up to $44.61 billion from $43.16 billion the year before, but underlying earnings before interest, tax, depreciation and amortisation jumped 13% to $23.90 billion from $21.19 billion. Net earnings jumped even higher, g
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza: IDMC recommend early analysis of OlympiA investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi view more
Credit: Ludwig Cancer Research
FEBRUARY 15, 2021, NEW YORK - A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors. The tumors in question are relatively less reliant on burning sugar through a biochemical process known as glycolysis.
Researchers led by Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi now at Weill Cornell Medicine have discovered that in a mouse model of glycolysis-deficient tumors, CTLA-4 blockade does much more than stimulate cancer-targeting T cells of the immune system. In such tumors, anti-CTLA-4 therapy also destabilizes and reprograms regulatory T
AstraZeneca (LSE:AZN) | RNS | AstraZeneca PLC - Lynparza: IDMC recommend early analysis of OlympiA proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.